The impact of COVID vaccination on symptoms of Long Covid. An international survey of 900 people with lived experience (May 2021)

Summary

In March 2021 the advocacy group LongCovidSOS launched a survey in partnership with the University of Exeter and University of Kent to find out how people with Long Covid respond to COVID-19 vaccines.

The analysis, which is yet to be peer reviewed showed that 56.7% of respondents experienced an overall improvement in symptoms, with 24.6% remaining unchanged and 18.7% reporting a deterioration in their symptoms.

In general, those who received mRNA vaccines (Pfizer/BioNTech or Moderna) reported more improvements in symptoms, compared with those who got an adenovirus vaccine (Oxford/AstraZeneca). In particular, those who received the Moderna vaccine were more likely to see improvements in symptoms such as fatigue, brain fog and muscle pain, and less likely to report a deterioration, the analysis found.